0.00Open0.00Pre Close0 Volume0 Open Interest90.00Strike Price0.00Turnover255.45%IV-15.24%PremiumNov 29, 2024Expiry Date11.90Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8951Delta0.0215Gamma6.35Leverage Ratio-1.1386Theta-0.0013Rho-5.68Eff Leverage0.0060Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet